Last month, the NICE endorsed Casgevy for use in the NHS under a managed access scheme to treat sickle cell disease.

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts signal growth. Click for my CRSP update.

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...

Despite slower-than-expected Casgevy enrollment, Crispr's strong cash position and diversified drug pipeline bolster its long-term growth potential. Clinical progress includes expanding authorized ...

This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...

The biotech's Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals, is now approved in the U.S ...